Cidofovir
Based on 14 publication(s) in Google Scholar
Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir also has anti-orthopoxvirus and anti-variola activities.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.95%
- CAS No.: 113852-37-2
- Formule: C8H14N3O6P
- Masse moléculaire:279.19
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Tumorigenesis-Related Compound Library
HY-L100
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Orthopoxvirus Compound Library
HY-L127
-
Off-patent Drug Library
HY-L141
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Cidofovir
More- Int J Biol Macromol. 2026 Mar:352:151224. [Abstract]
- Int J Biol Macromol. 2026 Mar:350:150992. [Abstract]
- Phytomedicine. 2025 May 24:143:156884. [Abstract]
- Emerg Microbes Infect. 2023 Dec;12(1):2208682. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117120. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Pharmaceuticals (Basel). 2025 Oct 16;18(10):1560. [Abstract]
- Poult Sci. 2024 Dec;103(12):104238. [Abstract]
- Pestic Biochem Physiol. 2026 Jan;216(Pt 1):106738. [Abstract]
- Virol Sin. 2025 Mar 25:S1995-820X(25)00031-8. [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- J Virol. 2025 Jan 23:e0153924. [Abstract]
- Microb Pathog. 2026 Apr:213:108349. [Abstract]
- Viruses. 2021 Oct 18;13(10):2102. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
RT-PCR
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
MoreVoir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
DNA Polymerase |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ARPE-19 | CC50 |
>100 μM
Compound: CDV
|
Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability treated for 72 hrs by neutral red assay
Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability treated for 72 hrs by neutral red assay
|
[PMID: 37140467] |
| HEL | CC50 |
64 μM
Compound: Cidofovir
|
Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs
Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs
|
[PMID: 38643669] |
| HFF | CC50 |
>150 μM
Compound: 34
|
Cytotoxicity against human HFF cells assessed as cell growth inhibition by celltiter-glo assay
Cytotoxicity against human HFF cells assessed as cell growth inhibition by celltiter-glo assay
|
[PMID: 38784469] |
Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner[1].
Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Crandell-Reese feline kidney(CRFK) cells
-
Concentration:10-100 μM
-
Incubation Time:72 hours
-
Result:Reduced CRFK cells by 9.1%.
-
Cell Line:Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells
-
Concentration:10-1000 μM
-
Incubation Time:24, 48, 72, 96, 120 hours
-
Result:Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.
-
Cell Line:FTC-133 cells
-
Concentration:100 μM
-
Incubation Time:96 hours
-
Result:Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female weanling BALB/c mice infected with cowpox virus (CPV)[2]
-
Dosage:100 mg/kg
-
Administration:Subcutaneous injection; 3-6 days interval; 21 days
-
Result:Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.
Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.
Chemical Information
-
CAS No. 113852-37-2
-
Appearance Solid
-
Masse moléculaire 279.19
-
Formule C8H14N3O6P
-
Color White to off-white
-
SMILES
OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O
-
Synonyms
GS 0504; HPMPC; (S)-HPMPC
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543 -
Int J Biol Macromol
Unveiling the mechanistic link between peroxiredoxin inhibition and ferroptosis-like cell death induced by Dinaciclib in Entamoeba histolytica. [Abstract]2026 Mar:350:150992. PMID: 41713546 -
Phytomedicine
Calycosin inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by downregulating early growth response 1. [Abstract]2025 May 24:143:156884. PMID: 40446581 -
Emerg Microbes Infect
The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China. [Abstract]2023 Dec;12(1):2208682. PMID: 37128898
Cidofovir purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2023 Dec;12(1):2208682. [Abstract]
Cytotoxicity of Cidofovir and its Inhibition efficiency on WIBP-MPXV-001
-
Biochem Pharmacol
Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]2025 Oct:240:117120. PMID: 40623460 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Pharmaceuticals (Basel)
New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors. [Abstract]2025 Oct 16;18(10):1560. PMID: 41155676
Cidofovir purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Oct 16;18(10):1560. [Abstract]
The cytotoxicity of three reference compounds (GCV, CDV (Cidofovir), and BCV) on COS-7 cells was tested.
-
Poult Sci
Up-regulated Lnc BTU promotes the production of duck plague virus DNA polymerase and inhibits the activation of JAK-STAT pathway to facilitate duck plague virus replication. [Abstract]2024 Dec;103(12):104238. PMID: 39383668
Cidofovir purchased from MedChemExpress. Usage Cited in: Poult Sci. 2024 Dec;103(12):104238. [Abstract]
DEFs infected DPV at MOI=1, then treated with Cidofovir (10 nmol) for 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h and 16 h, qRT-PCR detected DPV copy numbers in the supernatant.
-
Pestic Biochem Physiol
Cidofovir induces antiviral immunity against Bombyx mori nucleopolyhedrovirus by modulating multiple immune pathways in silkworm. [Abstract]2026 Jan;216(Pt 1):106738. PMID: 41326100 -
Virol Sin
Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
Cidofovir purchased from MedChemExpress. Usage Cited in: Virol Sin. 2025 Mar 25:S1995-820X(25)00031-8. [Abstract]
HEK293T cells were transfected with pHBoV1-HiBiTNS1 in the presence of Cidofovir (200 μM), favipiravir (50 μM), ivermectin (10 μM), nevirapine (50 μM), remdesivir (10 μM), ribavirin (50 μM), sofosbuvir (50 μM), or zidovudin (50 μM). At 72 h post-transfection, the Nano-Glo luciferase assay was performed.
-
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
J Virol
2025 Jan 23:e0153924. PMID: 39846742
Cidofovir purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jan 23:e0153924. [Abstract]
Antiviral activity of cidofovir against HBoV1. MA104 cells were treated with 50, 100, 200, 400 µM cidofovir for 6 h and then infected with HBoV1 for 12 h, and the intracellular viral DNA copies were detected at 96 h.p.i.
-
Microb Pathog
mTORC2-dependent autophagy inhibition regulates the replication of HSV-1 and adenovirus in viral keratitis & conjunctivitis. [Abstract]2026 Apr:213:108349. PMID: 41628839 -
Viruses
Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model. [Abstract]2021 Oct 18;13(10):2102. PMID: 34696532
Solvant et solubilité
H2O : 3.33 mg/mL (11.93 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 4.55 mg/mL (16.30 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]
[2]. M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9. [Content Brief]
[3]. Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55. [Content Brief]
[4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.5818 mL | 17.9090 mL | 35.8179 mL | 89.5448 mL |
| 5 mM | 0.7164 mL | 3.5818 mL | 7.1636 mL | 17.9090 mL | |
| 10 mM | 0.3582 mL | 1.7909 mL | 3.5818 mL | 8.9545 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz